ALMR
Alamar Biosciences, Inc.
Set alert
- YTD
- +39.09%
- 1 year
- +39.09%
- Open
- 33.35
- Prev close
- 34.04
- Mkt cap
- 2.12B
- Vol
- 740.07K
- Avg vol
- 537.55K
- EPS
- -1.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 29.36
- High
- 33.85
- Forward P/E
- -66.64
- Beta
- 0.00
- Short ratio
- 3.53
- Inst. own
- 57.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 30.73
- 200-d avg
- 26.90
- 1y target
- 35.40
News
2 days ago globenewswire.com
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations…
3 weeks ago seekingalpha.com
Alamar: The Consumables Flywheel Is Just Getting Started
Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. 2Q26 revenue surged 82% YoY to $29.4M, with consumables up 147% and now…
3 weeks ago globenewswire.com
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer Strengthens leadership team with appointments of John Brottem as general…
1 month ago globenewswire.com
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from…
1 month ago benzinga.com
Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed as the Dow fell 150 points; Mistras surged on a $20.35/share buyout deal, while crypto and tech stocks gained.
1 month ago seekingalpha.com
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4%…
2 months ago seekingalpha.com
Alamar Biosciences: Promising But Expensive Proteomics Growth
Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and…
2 months ago seekingalpha.com
Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument
Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to…
2 months ago benzinga.com
Top 3 Health Care Stocks That May Implode In August
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
2 months ago defenseworld.net
Alamar Biosciences Q2 Earnings Call Highlights
Alamar Biosciences (NASDAQ: ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue…
-
2 months ago benzinga.com
Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32
Stifel analyst Daniel Arias maintains Alamar Biosciences (NASDAQ:ALMR) with a Buy and raises the price target from $28 to $32.
2 months ago benzinga.com
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences Inc. (NASDAQ:ALMR) shares are trading higher on Tuesday as the company is expanding its global partnership with the Alzheimer's Disease Data Initiative and Gates Ventures.
2 months ago benzinga.com
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences expands its Alzheimer’s data partnership, adds 86,000 samples and reports Q2 sales growth of 82% year-over-year.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Alamar Biosciences, Raises Price Target to $35
JP Morgan analyst Casey Woodring maintains Alamar Biosciences (NASDAQ:ALMR) with a Overweight and raises the price target from $32 to $35.
2 months ago benzinga.com
Quantum, Kopin, Alamar Biosciences And Other Big Stocks Moving Higher On Tuesday
QMCO gained 44% after reporting strong Q1 earnings and guidance above estimates. Other gainers include NIQ, RPD, KOPN, FRMI, ALMR, MG, BW, SE, RNW, and RIOT.
2 months ago seekingalpha.com
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Alamar Biosciences Q2 Earnings Call Highlights
Alamar Biosciences NASDAQ: ALMR reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue…
-
2 months ago benzinga.com
Alamar Biosciences Sees FY2026 Sales $116.000M-$120.000M vs $113.259M Est
Alamar Biosciences (NASDAQ:ALMR) sees FY2026 sales of $116.000 million-$120.000 million vs $113.259 million analyst estimate.
3 months ago globenewswire.com
Alamar Biosciences 推出 NULISAseq™ Immune 340 Panel，实现免疫蛋白质组全面分析
扩展检测面板将进一步推动癌症、心血管与代谢疾病、自身免疫性疾病及衰老等领域转化与临床研究中的免疫系统认知 高灵敏度多重检测，可捕获标准平台常遗漏的调控蛋白（如免疫检查点抑制剂）及低丰度靶标 加利福尼亚州弗里蒙特, July 30, 2026 (GLOBE NEWSWIRE) -- 致力于推动疾病早期检测的精准蛋白质组学领军企业 Alamar Biosciences, Inc. (Nasdaq:…
3 months ago globenewswire.com
Alamar Biosciences 推出 NULISAseq™ Immune 340 Panel 檢測組合，為免疫蛋白質體作全面分析
擴展的檢測組合有助加深對免疫系統的理解，並且推動癌症、心血管與代謝疾病、自體免疫疾病和衰老方面的轉化研究及臨床研究向前發展 高靈敏度的多重檢測技術，能捕捉到免疫檢查點抑制劑等調控蛋白和低豐度目標，而這些通常是標準平台是無法檢測出來的 加州佛利蒙, July 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR)…
-
3 months ago benzinga.com
Alamar Biosciences Launches NULISAseq Immune 340 Panel, Broadest Multiplexed Immune Profiling Solution Available For Translational Research And Drug Development
Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the launch of the NULISAseq™ Immune 340 Panel, its…
3 months ago globenewswire.com
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
3 months ago globenewswire.com
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Fremont, CA, July 28, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the…
3 months ago globenewswire.com
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced…
3 months ago globenewswire.com
Alamar Biosciences 联合多所顶尖研究型大学推出全国性研究计划，推进神经退行性疾病血液生物标志物相关研究
这项全国性研究计划将利用 Alamar Biosciences 的 NULISAseq Neuro 220 检测试剂盒，对 10,000 名阿尔茨海默病及相关痴呆症 (ADRD) 受试者提供的约 21,000 万份血浆样本开展图谱分析。 生成的数据集将对外开放，可通过 National Alzheimer's Coordinating Center (美国国家阿尔茨海默病协调中心)…
-
3 months ago globenewswire.com
Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究
這項全國計劃會採用 Alamar Biosciences 的 NULISAseq Neuro 220 多重檢測組合試劑盒，分析來自 10,000 名阿茲海默症及相關認知障礙症 (ADRD) 參與者約 21,000 份的血漿樣本。 研究所得的數據集將全面開放，經由 National Alzheimer's Coordinating Center…
3 months ago globenewswire.com
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced a…
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
4 months ago benzinga.com
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results. Other stocks declining in pre-market trading.
4 months ago benzinga.com
Why Friedman Industries Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Friedman Industries Inc (NASDAQ: FRD) rose in pre-market trading after posting strong Q4 earnings. Other gainers include BYAH, VSME, ADTX, EDHL, GMM, HKIT, RKTO, ASYS, and PWRL. Losers include GELS,…
5 months ago benzinga.com
This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM, SWX, KLRA. See what they think of SWX stock.